home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2845.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
44 lines
Document 2845
DOCN M94A2845
TI First evaluation of 20 HIV positive patients on treatment of AZT/ddI at
the L.J. Engelmajer Association.
DT 9412
AU Puchot P; Puppo P; Engelmajer ML; European Institute for Documentation
and Research on Drug Abuse,; Grenade, France.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):211 (abstract no. PB0275). Unique
Identifier : AIDSLINE ICA10/94369730
AB BACKGROUND: Numerous interesting works published in Berlin demonstrating
the benefit of treatments with Combined convergents associating the
Nucleoside Analogues (AZT + DDI or AZT + DDC) taking into consideration
the appearance of viral resistance induced by reverse transcriptase
mutations. METHOD: Twenty patients during a period of 4 months: Four
patients were switched directly from AZT only to the association of
AZT/DDI, Sixteen patients were being treated with DDI as monotherapy for
two months before receiving the associated treatment. RESULTS: The
results were evaluated according to the following: 1) The evolution of
values of Absolute CD4 count and percentage of Total Lymphocyte count
(see Graphics) 2) The evolution of values of P24 antigen and P24
antibodies (see Graphics). 3) The associated treatment was interrupted
in 3 patients for the following causes: Acute pancreatitis of iatrogenic
origin, Herpes Zoster, treated with Zovirax, A PCP (pneumocystis
carinii), treated with Bactrim was followed by a CMV infection with a
localization at the retina for which treatment with Foscavir was
initiated and continues presently. CONCLUSIONS: The duration of
follow-up of the 20 patients that are receiving the associated treatment
is only 4 months. It is not yet sufficient time to be able to evaluate
its efficacy and tolerance, but we can state that apparently the
association of both medications is much more effective than a
monotherapy.
DE AIDS-Related Opportunistic Infections/PREVENTION & CONTROL
Didanosine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC USE
Drug Synergism Drug Therapy, Combination Human HIV Antibodies/BLOOD
HIV Core Protein p24/BLOOD HIV Infections/*DRUG THERAPY Leukocyte
Count Pancreatitis/CHEMICALLY INDUCED Treatment Outcome T4
Lymphocytes Zalcitabine/ADMINISTRATION & DOSAGE/ADVERSE
EFFECTS/*THERAPEUTIC USE Zidovudine/ADMINISTRATION & DOSAGE/ADVERSE
EFFECTS/*THERAPEUTIC USE CLINICAL TRIAL MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).